InsiderTrades

Form 4 for SPTX Seaport Therapeutics, Inc.

Accepted 2026-05-04 18:06:29 ET · period of report 2026-04-30 · accession 0001193125-26-204468 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2026-05-04 18:06 2026-05-04 SPTX Torres Denice Dir C - Cnv Deriv — +13.4K 13.4K New —
D 2026-05-04 18:06 2026-04-30 SPTX Torres Denice Dir A - Grant $0.00 +12.3K 12.3K New $0
DI 2026-05-04 18:06 2026-05-04 SPTX Torres Denice Dir C - Cnv Deriv $0.00 -42.1K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-05-04 C A 13,406 — 13,406 I By Denice M. Torres Revocable Trust — — (F1) Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. (F2) The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
2 Derivative Stock Option (Right to Buy) 2026-04-30 A A 12,258 $0.00 12,258 D $18.00 · — to 2036-04-29 12,258 Common Stock (F3) The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.
3 Derivative Series B Preferred Stock 2026-05-04 C D 42,105 $0.00 0 I By Denice M. Torres Revocable Trust — · — to — 13,406 Common Stock (F1) Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. (F1) Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. (F1) Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. (F2) The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.